Patients hospitalized for COVID-19 had higher levels over the short term of blood proteins known to rise with neurological damage than non-COVID-19 patients diagnosed with Alzheimer’s disease, a new study finds.
Importantly, the current report, published online January 13 in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, was conducted over two months early in the pandemic (March-May 2020). Any determination of whether patients with COVID-19 are at increased risk for future Alzheimer’s disease, or instead recover over time, must await the outcomes of long-term…
